It is noteworthy that, in GCT of different histologies, cytotoxicity facilitated by the EpCAM/CD3-binding bAb Catumaxomab is stable over a broad range of antibody concentrations from 1 μg/mL down to 0.0001 μg/mL, the latter corresponding to plasma levels achieved after intravenous administration of the lowest dose in a phase I dose-escalation study [27]. Here, EPCAM is linked to granular cell tumor.